Tatva Chintan Pharma schedules analyst meet with Motilal Oswal AMC

Tatva Chintan Pharma Chem Limited has scheduled a virtual one-to-one meeting with Motilal Oswal AMC on July 31, 2026. The engagement is part of the company’s ongoing investor relations activities and aims to provide financial institutions with updates based on publicly available data. This interaction ensures transparency and adherence to regulatory disclosure norms without sharing any unpublished price-sensitive information (UPSI).

The meeting was intimated to the Bombay Stock Exchange and the National Stock Exchange of India Limited on July 24, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ishwar Nayi, Company Secretary and Compliance Officer, signed the disclosure, confirming that discussions will be strictly limited to information already available to the public.

Meeting Details

The schedule for the investor interaction is outlined below:

Date	Analyst/Financial Institution	Type	Mode
July 31, 2026	Motilal Oswal AMC	One to One Meeting	Virtual Meeting

Regulatory Compliance

The company emphasized that no confidential or UPSI will be shared during the session. All information discussed will refer only to what is already accessible through official channels. The intimation is also available on the company’s website at www.tatvachintan.com . Any changes to the schedule will be communicated separately.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.52%	+3.53%	+45.85%	+49.36%	+53.78%	-24.56%

Tatva Chintan Pharma Chem Limited will host a virtual one-to-one meeting with Ventura Securities Limited on July 30, 2026. The engagement is part of the company’s ongoing investor relations activities and aims to provide financial institutions and analysts with an opportunity to discuss the business based on publicly available data. Management emphasized that no unpublished price-sensitive information (UPSI) will be shared during the interaction, ensuring compliance with market regulations.

The intimation was submitted to the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ishwar Nayi, Company Secretary and Compliance Officer, signed the disclosure on July 24, 2026. The schedule is subject to change, though no alternative dates have been proposed in the filing.

Meeting Details

Date	Participant	Type	Mode
July 30, 2026	Ventura Securities Limited	One to One Meeting	Virtual Meeting

The company noted that all discussions will be confined to publicly available information. This approach aligns with standard regulatory practices for investor interactions, preventing any potential leakage of material non-public information. The details of the meeting are also available on the company’s website at www.tatvachintan.com .

Regulatory Compliance

Under Regulation 30 of the SEBI LODR Regulations, listed entities must promptly disclose schedules for meetings with analysts, financial institutions, or investors. This ensures transparency and equal access to information for all stakeholders. By explicitly stating that UPSI will not be discussed, Tatva Chintan Pharma reinforces its adherence to fair disclosure norms. The filing serves as a formal record for the exchanges and investors, maintaining the integrity of the capital markets.